4-aminoquinoline-3-carbaldehyde | 63481-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-aminoquinoline-3-carbaldehyde
• 英文别名: amino-4 formyl-3 quinoleine；4-amino-quinoline-3-carbaldehyde
• CAS: 63481-70-9
• 化学式: C₁₀H₈N₂O
• mdl: MFCD18448403
• 分子量: 172.186
• InChiKey: HPGFJXMUEPXRRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-aminoquinoline-3-carbaldehyde 在 盐酸羟胺 、 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 N-[(4-aminoquinolin-3-yl)methylidene]hydroxylamine
  参考文献：
  名称：

  Godard, Alain; Queguiner, Guy, Journal of Heterocyclic Chemistry, 1980, vol. 17, p. 465 - 473

  摘要：

  DOI：
• 作为产物：
  描述：

  amino-4 quinoleinecarboxylate de methyle-3 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 13.0h， 生成 4-aminoquinoline-3-carbaldehyde
  参考文献：
  名称：

  Godard, Alain; Queguiner, Guy, Journal of Heterocyclic Chemistry, 1980, vol. 17, p. 465 - 473

  摘要：

  DOI：

文献信息

• Nitrosated proton pump inhibitors, compositions and methods of use
  申请人：NitroMed, Inc.

  公开号：US20040024014A1

  公开（公告）日：2004-02-05

  The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.

  该发明描述了新颖的亚硝化质子泵抑制剂化合物及其药用盐，以及包含至少一种亚硝化质子泵抑制剂化合物的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种亚硝化质子泵抑制剂化合物和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种亚硝化质子泵抑制剂化合物，可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型套装。该发明还提供了治疗胃肠道疾病的方法；促进溃疡愈合；减少溃疡复发；改善质子泵抑制剂的胃保护性能、抗幽门螺杆菌性能或抗酸性能；减少或减轻与非甾体类抗炎化合物使用相关的胃肠毒性；治疗细菌感染和/或病毒感染。
• Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
  申请人：NitroMed, Inc.

  公开号：US20040266828A1

  公开（公告）日：2004-12-30

  The present invention describes novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers, or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one nonsteroidal antiinflammatory drug, selective COX-2 inhibitor, antacid, bismuth-containing reagent, acid-degradable antibacterial compound, and mixtures thereof. The present invention also provides methods for treating and/or preventing gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylon properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating Helicobacter pylori and viral infections. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

  本发明描述了新型的硝化和/或亚硝化质子泵抑制剂化合物，以及包含至少一种质子泵抑制剂化合物的新型组合物，该化合物可以选择地取代至少一个NO和/或NO2基团，并且可以选择地包含至少一种提供、转移或释放一氧化氮、诱导内源性一氧化氮或内皮源性舒张因子产生、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或至少一种非甾体抗炎药、选择性COX-2抑制剂、抗酸剂、含铋试剂、酸降解抗菌化合物及其混合物。本发明还提供了治疗和/或预防胃肠道疾病的方法；促进溃疡愈合；减少溃疡复发；改善质子泵抑制剂的胃保护性能、抗幽门螺杆菌性能或抗酸性能；减少或降低与非甾体抗炎化合物使用相关的胃肠道毒性；治疗幽门螺杆菌和病毒感染。本发明的化合物和/或组合物还可以以药用工具包的形式提供。
• Interesting Results of Catalytic Hydrogenation of 3-(2-Nitrophenyl)isoxazoles and 3-(Nitrophenyl)-4,5-dihydroisoxazoles
  作者：S. Batra、V. Singh、S. Madapa、G. Yadav、P. Maulik

  DOI：10.1055/s-2006-942388

  日期：2006.6

  hydrogenolysis of substituted 3-(2-nitrophenyl)isoxazoles, irrespective of substitution on the isoxazole ring, invariably leads to reduction of the nitro to the amino group with concomitant regiospecific ring closure to yield substituted 4-aminoquinolines. In contrast similar hydrogenation of 3-(2-, 3-, and 4-nitrophenyl)-4,5-dihydroisoxazoles (2-isoxazolines) results in reduction of the nitro group only

  取代的 3-(2-硝基苯基) 异恶唑的钯碳辅助氢解，无论异恶唑环上的取代如何，都会导致硝基还原为氨基，同时伴随区域特异性闭环产生取代的 4-氨基喹啉。相比之下，类似的 3-(2-、3- 和 4-硝基苯基)-4,5-二氢异恶唑 (2-异恶唑啉) 的氢化导致硝基还原，仅保留二氢异恶唑环，得到相应的 3- (氨基苯基)-4,5-二氢异恶唑。
• TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF
  申请人：Shanghai Xiangjin Biotechnology Co., Ltd

  公开号：EP3511327A1

  公开（公告）日：2019-07-17

  The invention discloses a compound with the general formula of (I), wherein, K is selected from: naphthene alkyl and haloalkane alkyl or N-R6. The invention also discloses a tyrosine kinase inhibitor containing the above compound and the application of the compound in preparing drugs for treating cancers. The tyrosine kinase inhibitor of the invention inhibit the bioactivity of multiple signal conduction kinases such as C-MET, VEGF, KDR, etc., it can effectively inhibit cell proliferation and has favorable therapeutic effects on various diseases such as cancer, it has significant therapeutic effects especially on lung cancer, gastric cancer, ovarian cancer, malignant glioma, etc., and it has a very broad application prospect.

  本发明公开了一种通式为（I）的化合物，其中，K 选自：萘烷基 和卤代烷基 或 N-R6。本发明还公开了一种含有上述化合物的酪氨酸激酶抑制剂，以及该化合物在制备治疗癌症药物中的应用。本发明的酪氨酸激酶抑制剂抑制C-MET、VEGF、KDR等多种信号传导激酶的生物活性，能有效抑制细胞增殖，对癌症等多种疾病有良好的治疗作用，尤其对肺癌、胃癌、卵巢癌、恶性胶质瘤等有显著的治疗效果，具有非常广阔的应用前景。
• Tyrosine kinase inhibitor and application thereof
  申请人：LaNova Medicines Limited

  公开号：US10882853B2

  公开（公告）日：2021-01-05

  The invention discloses a compound with the following formula (I), wherein, K is selected from: cycloalkyl and halo alkyl or N—R6. The invention also discloses a tyrosine kinase inhibitor containing the above compound and the use of the compound in preparing drugs for treating cancers. The tyrosine kinase inhibitor of the invention can inhibit the bioactivity of multiple signal conduction kinases such as C-MET, VEGF, KDR, etc., can effectively inhibit cell proliferation and has favorable therapeutic effects on various diseases such as cancer. In particular, the present invention has significant therapeutic effects especially on lung cancer, gastric cancer, ovarian cancer, malignant glioma, etc., and has a very broad application prospect.

  本发明公开了一种具有下式（I）的化合物，其中，K 选自： 环烷基 和卤代烷基 或 N-R6。本发明还公开了一种含有上述化合物的酪氨酸激酶抑制剂以及该化合物在制备治疗癌症药物中的应用。本发明的酪氨酸激酶抑制剂能抑制多种信号传导激酶如 C-MET、VEGF、KDR 等的生物活性，能有效抑制细胞增殖，对癌症等多种疾病具有良好的治疗效果。特别是本发明对肺癌、胃癌、卵巢癌、恶性胶质瘤等具有显著的治疗效果，应用前景十分广阔。